NSAIDs Rx class labeling should reflect recent GI risk research -- Arthritis Advisory Cmte.
This article was originally published in The Tan Sheet
Executive Summary
Rx NSAID GASTROPATHY CLASS WARNING UPDATE ADVISED to reflect current research on gastrointestinal (GI) risks posed by prescription nonsteroidal anti-inflammatory drugs, FDA's Arthritis Advisory Committee unanimously recommended at its Oct. 12 meeting. The meeting was structured as an open forum for suggestions from the committee and guests. The discussion, however, was limited to physician labeling of Rx NSAIDs.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning